Revive Therapeutics Updates, on Phase III Clinical Trial!

Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.." Revive Therapeutics Provides Update on...

Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...

Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Not wanting to be caught flat-footed upon potential approval, Revive is...

Revive (RVVTF) Hits a Snag?

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 First our summary."FDA provided communication that the amended protocol is still under...

Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...

Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings. Ardelyx ( NASDAQ: ARDX ) gained 35% Friday after the biotech reported better-than-expected financials...
Revive Therapeutics

Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...

Two Binary Events Directly Ahead. As in Months Away, not Years. Share Price up 76% During April. As we stated earlier, Revive Therapeutics (RVVTF)...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...

Adding Ardelyx (ARDX) $1.57 to Watch List.

FDA Advisory Committee Says Go Forth Young Man! While we hadn't previously owned Ardelyx, nor are they a client - there are a number of...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers. Definitely NOT for traders or...

And We Have a $26.4 Billion Winning Trifecta!

THREE PREVIOUS WINNERS* Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired by Gilead Sciences (GILD) Dicerna (DRNA) $3.30 to $38.25 up...

Latest article

Americore (AMCOF) Funding Launched. Looks Like Good Entry Point.

All Systems Go? 2025 WATCH LIST 2026 WATCH LIST LIVE QUOTE REPORT POWER POINT

Society Pass (SOPA) Files Chapter 11.

So sad.. No 8k filing yet (05/13/2026), just a news story. 8K SEC filing page SEC (allow time to load) 05/14/26 SOPA 8k filing 5/13/2026 NUTR 8K filing What...

When Secure Communications is Absolutely Paramount to Mission Success. Sekur Private Data (SWISF).

Sekur (SWISF) $0.05 Headed to Huge Special Ops Military Convention in Tampa FL. Will Demonstrate it's "SekurVoice" Solution, to Special Ops Buyers, Designed for...